European annals of allergy and clinical immunology最新文献_第4页

Ultrafast regimen for Pru p3 sublingual immunotherapy (SLIT-Peach®) in patients with anaphylactic LTP-Syndrome. 针对过敏性 LTP-Syndrome 患者的 Pru p3 舌下免疫疗法（SLIT-Peach®）超快速疗法。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-07-01 Epub Date: 2023-02-14 DOI: 10.23822/EurAnnACI.1764-1489.285

M S Zamarro Parra, Y Petryk Petryk, J Carbonell Zamoran, A Carbonell Martinez

{"title":"Ultrafast regimen for Pru p3 sublingual immunotherapy (SLIT-Peach®) in patients with anaphylactic LTP-Syndrome.","authors":"M S Zamarro Parra, Y Petryk Petryk, J Carbonell Zamoran, A Carbonell Martinez","doi":"10.23822/EurAnnACI.1764-1489.285","DOIUrl":"10.23822/EurAnnACI.1764-1489.285","url":null,"abstract":"Summary: Sublingual immunotherapy with Pru p3 extract (SLIT-peach®) is used in allergy patients to multiple plant foods to induce tolerance to nonspecific lipid transfer proteins (nsLTP). The aim of this paper is to communicate the efficacy of a new ultrafast regimen. Until now on the initiation regimen lasts four days. We present a number of 22 patients with LTP-syndrome due to ingestion of different vegetable foods sensitized to Pru p3. According to European Academy of Allergy position paper (1) food immunotherapy is indicated when avoidance measures are ineffective, undesirable, or cause serious limitations on patients quality of life. Our patients had an impact on their quality of life (score > 130) before SLIT measured with (2) EuroPrevall Food Allergy Quality of Life Questionnaire (FAQLQ). The ultrafast regimen in one day is achieved in the 95% of our patients. Mild adverse reactions were observed, such as oral pruritus presence in almost all patients. Only one patient (5%) achieved the maintenance dose in two days due to intense oral pruritus. No patients presented systemic reactions. The maintenance dose achieved consists of 4 drops (0,16 ml) from vial number 4 daily. The concentration of Pru p3 in vial nº4 is 50 cg/ml. Four drops a day equals 8 micrograms of Pru p3. This new ultrafast regimen in one day is secure in patients with LTP-Syndrome to induce tolerance to SLIT-peach® (Pru p3 extract).","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10706899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A real-life cohort of mepolizumab treatment in severe eosinophilic asthma. 美妥珠单抗治疗重度嗜酸性粒细胞性哮喘的真实队列。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-07-01 Epub Date: 2023-03-16 DOI: 10.23822/EurAnnACI.1764-1489.289

D Laorden, I Hernández, J Domínguez-Ortega, D Romero, R Álvarez-Sala, S Quirce

{"title":"A real-life cohort of mepolizumab treatment in severe eosinophilic asthma.","authors":"D Laorden, I Hernández, J Domínguez-Ortega, D Romero, R Álvarez-Sala, S Quirce","doi":"10.23822/EurAnnACI.1764-1489.289","DOIUrl":"10.23822/EurAnnACI.1764-1489.289","url":null,"abstract":"Summary: Background. Mepolizumab, a monoclonal antibody that interacts with IL-5, was the first anti-IL-5 approved for uncontrolled severe eosinophilic asthma. In several randomised, placebo-controlled trials, treatment with mepolizumab has shown a significant improvement in asthma symptoms and the need to use of oral corticosteroids (OCS). Several studies have correlated blood levels of eosinophil cationic protein (ECP) with the degree of eosinophilic inflammation, which could make it an indirect marker of eosinophilic activity. Methods. This was a single-centre retrospective study that included all patients diagnosed with severe eosinophilic asthma under treatment with mepolizumab. We recorded the number of exacerbations, daily prednisone intake, asthma control test scores and forced expiratory volume in the first second. Results. We followed 22 patients, 14 of whom were OCS-dependent with a mean daily dose of 15.85 ± 15.62 mg prednisone. After 12 months, only five continued taking OCS and the mean daily dose was reduced by up to 2.50 ± 3.84 mg (p less than 0.007). The exacerbation rate at baseline was 2.91 ± 2.27 and decreased to 0.82 ± 1.14 in the following year (p less than 0.001). ACT scores increased significantly from 16.00 ± 5.85 to 20.71 ± 4.45 after six months (p = 0.003). We also observed a decrease in ECP from 81.46 ± 43.99 µg/L to 19.12 ± 18.80 µg/L (p > 0.001). Conclusions. These real-life results are consistent with previous clinical trials demonstrating the efficacy and safety of mepolizumab in routine clinical practice for severe uncontrolled eosinophilic asthma. We observed a significant decrease in blood eosinophil counts and in ECP levels, suggesting a reduction in eosinophil activity following mepolizumab treatment.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9476301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical characterization of peach allergic patients and respective molecular sensitization profile with ALEX®2 macroarray. 利用 ALEX®2 宏阵列分析桃过敏症患者的临床特征和各自的分子致敏特征。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-07-01 Epub Date: 2023-02-14 DOI: 10.23822/EurAnnACI.1764-1489.284

M I T Silva, R Brás, M Paulino, F Cabral Duarte, M C Pereira Santos, C Costa

引用次数: 0

IgE-mediated reactivity to non-specific lipid transfer protein (nsLTP): clinical implications and management ‒ a consensus document of the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO). IgE介导的对非特异性脂质转移蛋白（nsLTP）的反应性：临床意义和管理——意大利地区和医院过敏学家和免疫学协会（AAIITO）的共识文件。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-07-01 Epub Date: 2023-10-20 DOI: 10.23822/EurAnnACI.1764-1489.316

R Asero, V Pravettoni, D Villalta, L Cecchi, E Scala

{"title":"IgE-mediated reactivity to non-specific lipid transfer protein (nsLTP): clinical implications and management ‒ a consensus document of the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO).","authors":"R Asero, V Pravettoni, D Villalta, L Cecchi, E Scala","doi":"10.23822/EurAnnACI.1764-1489.316","DOIUrl":"10.23822/EurAnnACI.1764-1489.316","url":null,"abstract":"Summary: The primary cause of adult-onset food allergy in Mediterranean countries is IgE-mediated reactivity to non-specific Lipid Transfer Protein (nsLTP), with a prevalence of 9.5% in Italy. nsLTP is heat- and pepsin-stable due to its 3D structure, causing severe allergic reactions, even anaphylaxis. It's conserved across plants and a \"panallergen\" due to homologous forms in various vegetable foods. Found in Rosaceae fruits' skin, it's categorized into nsLTP1 (9 kDa) and nsLTP2 (7 kDa), representing 93% and 7% of the molecules described to date, respectively. Pru p 3 (nsLTP1) from peach is a primary sensitizer, binding more epitopes than other homologs. Cross-reactivity varies in sensitized patients, influenced by IgE levels. Clinical manifestations range from none to various symptoms. Managing patients sensitized to nsLTP without clinical allergy is a challenge. Sensitization hierarchy usually starts with peach, then expands through Prunoideae, Rosaceae, and other foods. Clinical symptoms don't always expand across LTPs. Patients can tolerate some nsLTP-containing foods and consuming them may maintain tolerance. The absence of guidelines led to the Associazione Allergologi Immunologi Italiani Territoriali e Ospedalieri (AAIITO) creating a consensus-based document. Strategies involve avoidance, self-injectable adrenaline, verification through in vivo and in vitro testing, considering cofactors, and peeling fruits. In localized reactions, abstinence is recommended if specific IgE is high. Concurrent pollinosis may complicates diagnosis, but may help management since symptoms are often less severe. Asymptomatic patients are advised to continue normal diets while considering cofactors and total IgE levels. Management strategies should be case-specific, based on expert Consensus Document.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing systemic reactions and venom immunotherapy in vespid-venom allergy: observations from a retrospective study of Portuguese patients. 处理蝰蛇毒液过敏的全身反应和毒液免疫疗法：对葡萄牙患者的回顾性研究观察。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-06-26 DOI: 10.23822/EurAnnACI.1764-1489.349

S C Ferreira, M Gomes, J Vieira, L Caldeira, M I Silva, M B Ferreira, E Pedro, J Cosme

{"title":"Managing systemic reactions and venom immunotherapy in vespid-venom allergy: observations from a retrospective study of Portuguese patients.","authors":"S C Ferreira, M Gomes, J Vieira, L Caldeira, M I Silva, M B Ferreira, E Pedro, J Cosme","doi":"10.23822/EurAnnACI.1764-1489.349","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.349","url":null,"abstract":"Summary: Background. Vespula spp. and Polistes spp. are relevant species in South Europe, with Vespa velutina nigrithorax (VVN) being considered a public health problem. We aimed to characterize a cohort of Portuguese patients referred for large local reaction (LLR) and/or systemic reaction (SR) to vespids. In patients treated with venom immunotherapy (VIT), induction protocol and frequency of adverse reactions were evaluated. Methods. Retrospective study including patients with LLR and SR to vespids referred to our Immunoallergology Department (2008-2022). Results. A total of 129 patients were evaluated, the majority were male adults (n = 77, 59.7%), from rural areas. From these, 51 patients had SR (Mueller classification: 7.8% grade I, 19.6% grade II, 37.3% grade III, 35.3% grade IV). We found no differences regarding the levels of total serum IgE, basal serum tryptase value, sIgE levels to the eliciting venom or their molecular components, regarding the severity of the SR that motivated the referral to our clinic. In the SR group, previous LLR Hymenoptera sting were reported in 15.7%. Thirty-eight patients (74.5%) initiated VIT: 22 with wasp venom, 14 with paper wasp venom and 2 with Vespa velutina venom. There was one mild systemic reaction, not requiring adrenaline and 4 LLR. Re-stings after VIT occurred in 16 patients, without any systemic or local reactions. Currently, eleven patients remain under VIT. Conclusions. Most vespid-venom allergic patients are male adults from rural areas. Sensitization to wasp venom was present in 52.9%, paper wasp in 33.3% and Vespa velutina in 13.7%. The frequency of adverse reactions during both induction and maintenance phases appears to be low. Despite a reduced sample size, our experience with VVN VIT, suggests its safety.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anaphylaxis biomarkers: present and future. 过敏性休克生物标志物：现状与未来。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-06-26 DOI: 10.23822/EurAnnACI.1764-1489.350

A Pampura, N Esakova, S Zimin, E Filippova

引用次数: 0

Impact of asthma on severe food-induced allergic reactions: a systematic review and meta-analysis. 哮喘对严重食物诱发过敏反应的影响：系统回顾和荟萃分析。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-06-26 DOI: 10.23822/EurAnnACI.1764-1489.351

M B Cilona, G A Ramirez, C Asperti, A Ferlito, G Benanti, S Nannipieri, R M Abdul Hadi, C Capellini, L Dagna, M Cottini, M-R Yacoub

{"title":"Impact of asthma on severe food-induced allergic reactions: a systematic review and meta-analysis.","authors":"M B Cilona, G A Ramirez, C Asperti, A Ferlito, G Benanti, S Nannipieri, R M Abdul Hadi, C Capellini, L Dagna, M Cottini, M-R Yacoub","doi":"10.23822/EurAnnACI.1764-1489.351","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.351","url":null,"abstract":"Summary: Background. Food allergy can range from mild to severe, life-threatening reactions with various symptoms and organ involvement. The impact of asthma on severe food-induced allergic reactions is not completely understood. In the hypothesis that asthma increases the risk of severe food-induced allergic reactions, the aim of this study is to compare the incidence of severe food-induced allergic reactions in patients with history of asthma compared with patients without history of asthma. Methods. We performed a systematic research on electronic databases, including PubMed, Scopus, and Web of Science. Observational studies, studies reporting medical characteristics of patients diagnosed with food allergy, and studies reporting medical history of patients with allergic reactions were included. The primary outcome was the incidence of severe food-induced allergic reactions in patients with history of asthma compared with patients without history of asthma. The protocol of this review was registered in PROSPERO (CRD42023448293). Results. Eight studies with a total of 90,367 patients met the inclusion criteria and were included, with a total population of 28,166 of patients with food allergy. The incidence of severe food-induced allergic reactions in patients with history of asthma compared with patients without history of asthma was increased (OR = 1.28; 95% CI 1.03-1.59; p = 0.03; I2 = 59%). Conclusions. Individuals with both food allergy and asthma are at high risk of severe, potentially fatal allergic reactions. Healthcare professionals should prioritize prevention and management strategies for these subjects.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular sensitization profile to grass and olive pollens in Portugal. 葡萄牙草花粉和橄榄花粉的分子致敏特征。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-06-24 DOI: 10.23822/EurAnnACI.1764-1489.347

J Cosme, E Pedro, M C Pereira-Santos, A Lopes, J Caiado, M Paulino

{"title":"Molecular sensitization profile to grass and olive pollens in Portugal.","authors":"J Cosme, E Pedro, M C Pereira-Santos, A Lopes, J Caiado, M Paulino","doi":"10.23822/EurAnnACI.1764-1489.347","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.347","url":null,"abstract":"Summary: Background. Grass and olive pollens have overlapping pollination periods and are common allergens in the Iberian Peninsula. The objective is to determine the sensitization pattern to major Phleum pratense and Olea europaea pollens in the Portuguese population with pollen allergic rhinitis (AR) using molecular allergen diagnosis (MAD). Methods. Seasonal AR patients (≥ 12 years), with positive skin prick tests (SPT) to Phleum and Olea were recruited from 16 centers. Using ALEX2, specific IgE to Phl p1, Phl p2, Phl p5, Phl p6, Phl p7, Phl p 12, Ole e1, Ole e7 and Ole e9 were determined. Immunoblotting of Olea allergic patients was performed. Results. Included 175 patients (55.4% female; mean age 31.6 ± 13.3 years; 85.7% adults; 40% asthmatic, Coast 28%/Inland 72% and North 29.1%/Centre 20.6%/South 50.3%). Considering Phleum MAD, 85.7% were sensitized to Phl p1, 45.7% to Phl p2, 50.3% to Phl p5, 45.7%, to Phl p6, 10.9% to Phl p7 and 22.9% to Phl p12. Sensitization to Ole e1 was found in 56.6%, to Ole e7 in 1.7% and Ole e9 in 3.4% patients. Sensitization to Phl p7 was more frequent in asthmatics (17.4% vs 6.6%; p = 0.044). Sensitization to Phl p5, Phl p6, Phl p12 and Ole e1 was more frequent in inland. Regarding sensitization patterns: 53.1% patients were sensitized to both species genuine´ sIgE, 38.3% to Phleum and 3.4% only to Olea species' sIgE. Immunoblotting of Olea allergic patients showed a high intensity band that may correspond to Ole e12. Conclusions. MAD showed \"genuine\" Grass and Olea sensitization in approximately 50% of our patients.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical spectrum of patients diagnosed with childhood mastocytosis: a retrospective single center experience. 儿童肥大细胞增多症患者的临床表现：单一中心的回顾性经验。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-06-24 DOI: 10.23822/EurAnnACI.1764-1489.348

A M Durmaz, Ö Özdemir

{"title":"Clinical spectrum of patients diagnosed with childhood mastocytosis: a retrospective single center experience.","authors":"A M Durmaz, Ö Özdemir","doi":"10.23822/EurAnnACI.1764-1489.348","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.348","url":null,"abstract":"Summary: Background. Pediatric cutaneous mastocytosis patients diagnosed and followed up by our specialist were enrolled in this study, and clinical and laboratory evaluations were retrospectively analyzed from patients' archived files. Methods. Patients, who applied to the Division of Pediatric Allergy And Immunology Unit of a University Training and Research Hospital between 01.01.2010 and 28.04.2021, were enrolled in this study. Results. Of the 33 patients included in the study, 11 (33.3%) were female and 22 (67.7%) were male. The median age of onset of the patient's complaints was 7 (0-60) months. The median age at diagnosis was 11 (2-64) months. Their complaints' median regression age was 54 (6-192) months. Resistant clinical findings were followed in 13 (39.4%) patients. Itching, redness, gastrointestinal symptoms, and maculopapular eruption were the most common complaints. The rashes were mostly polymorphic and larger than 1 cm. Heat was the most common trigger. Darier's sign was positive in 97% of the patients. Antihistamines were the most commonly used drug for prophylaxis and treatment. The autoinjector prescription rate was 24.2%. Conclusions. Quality of life was mildly affected in 48,5% of the patients based on the CDLQI scores. Thus, patients should be followed up through adolescence for the development of systemic signs and symptoms.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adrenalin use in Kounis syndrome: a well-unknown entity. 库尼斯综合征中肾上腺素的使用：一个鲜为人知的实体。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-06-24 DOI: 10.23822/EurAnnACI.1764-1489.346

Ö Özdemir

引用次数: 0